Blocking programmed cell death protein 1 (PD-1) and its ligand (PD-L1) with agents such as nivolumab and pembrolizumab has improved survival in cases of melanoma and non-small cell lung adenocarcinoma (90, 91). The gene discussed is PDCD1; the disease is melanoma.